PE20140469A1 - Induccion de tolerancia inmunologica utilizando metotrexato - Google Patents

Induccion de tolerancia inmunologica utilizando metotrexato

Info

Publication number
PE20140469A1
PE20140469A1 PE2013002499A PE2013002499A PE20140469A1 PE 20140469 A1 PE20140469 A1 PE 20140469A1 PE 2013002499 A PE2013002499 A PE 2013002499A PE 2013002499 A PE2013002499 A PE 2013002499A PE 20140469 A1 PE20140469 A1 PE 20140469A1
Authority
PE
Peru
Prior art keywords
subject
enzyme
immunological tolerance
cells
alpha
Prior art date
Application number
PE2013002499A
Other languages
English (en)
Spanish (es)
Inventor
Alexandra Joseph
Susan Richards
Melanie Ruzek
Richard Garman
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47177257&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140469(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PE20140469A1 publication Critical patent/PE20140469A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
PE2013002499A 2011-05-16 2012-05-03 Induccion de tolerancia inmunologica utilizando metotrexato PE20140469A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161486697P 2011-05-16 2011-05-16

Publications (1)

Publication Number Publication Date
PE20140469A1 true PE20140469A1 (es) 2014-04-23

Family

ID=47177257

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002499A PE20140469A1 (es) 2011-05-16 2012-05-03 Induccion de tolerancia inmunologica utilizando metotrexato

Country Status (28)

Country Link
US (3) US20140135337A1 (OSRAM)
EP (2) EP2709627B1 (OSRAM)
JP (3) JP6174572B2 (OSRAM)
KR (3) KR20140040744A (OSRAM)
CN (4) CN113209288A (OSRAM)
AU (1) AU2012256281B2 (OSRAM)
BR (1) BR112013029501A2 (OSRAM)
CA (1) CA2835819A1 (OSRAM)
CL (1) CL2013003298A1 (OSRAM)
CO (1) CO6841993A2 (OSRAM)
DO (1) DOP2013000268A (OSRAM)
EC (1) ECSP13013081A (OSRAM)
ES (1) ES2836823T3 (OSRAM)
GT (1) GT201300278A (OSRAM)
IL (2) IL229245B (OSRAM)
MA (1) MA35165B1 (OSRAM)
MX (1) MX2013013445A (OSRAM)
MY (1) MY173304A (OSRAM)
NI (1) NI201300121A (OSRAM)
PE (1) PE20140469A1 (OSRAM)
PH (1) PH12013502256A1 (OSRAM)
PT (1) PT2709627T (OSRAM)
RU (1) RU2674036C2 (OSRAM)
SG (1) SG194802A1 (OSRAM)
TN (1) TN2013000472A1 (OSRAM)
UA (1) UA117556C2 (OSRAM)
WO (1) WO2012158362A1 (OSRAM)
ZA (1) ZA201308315B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011139379A2 (en) * 2010-05-06 2011-11-10 Duke University A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
AU2012249553A1 (en) 2011-04-29 2013-10-24 Selecta Biociences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
MX2013013445A (es) 2011-05-16 2014-07-28 Genzyme Corp Induccion de tolerancia inmunologica utilizando metotrexato.
MX2015015231A (es) 2013-05-03 2016-07-06 Selecta Biosciences Inc Métodos y composiciones para mejorar las células t reguladoras de cd4+.
KR102631173B1 (ko) * 2013-06-04 2024-01-31 셀렉타 바이오사이언시즈, 인크. 비-면역억제성 항원 특이적 면역요법제의 반복 투여
IL292575A (en) 2014-09-07 2022-06-01 Selecta Biosciences Inc Methods and preparations for weakening immune responses by modulating gene expression in an antiviral transfer system
IL255010B2 (en) 2015-04-15 2024-01-01 Regeneron Pharma Methods of increasing strength and functionality with gdf8 inhibitors
JP2016213236A (ja) * 2015-04-30 2016-12-15 日東電工株式会社 半導体装置用フィルム、及び、半導体装置の製造方法
AU2018236123B2 (en) 2017-03-11 2024-04-18 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2018209300A1 (en) * 2017-05-12 2018-11-15 Duke University Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy
TWI821227B (zh) * 2017-12-22 2023-11-11 美商健臻公司 胺甲喋呤誘發的免疫耐受性之生物標記
WO2021159092A1 (en) 2020-02-08 2021-08-12 Genzyme Corporation Compositions and methods for treating pompe disease
TW202342057A (zh) * 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080325A (en) 1976-11-17 1978-03-21 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of methotrexate
US4558690A (en) 1982-01-26 1985-12-17 University Of Scranton Method of administration of chemotherapy to tumors
US5108987A (en) 1982-02-25 1992-04-28 Faulk Ward P Conjugates of proteins with anti-tumor agents
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
DE4000154A1 (de) 1990-01-04 1991-07-11 Symbiotec Gmbh Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
WO2005085294A1 (ja) 2004-03-05 2005-09-15 Denki Kagaku Kogyo Kabushiki Kaisha ヒアルロン酸−メトトレキサート結合体
US7884196B2 (en) 2004-10-06 2011-02-08 Oliver Lawless Vaccine composition comprising methylated DNA and immunomodulatory motifs
RU2445975C2 (ru) * 2006-03-02 2012-03-27 Алексион Фармасьютикалз, Инк. Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента
WO2008094937A2 (en) 2007-01-29 2008-08-07 Joslin Diabetes Center, Inc. Methods of modulating angiogenesis
US20090155207A1 (en) * 2007-11-29 2009-06-18 Hariri Robert J Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders
EP2077281A1 (en) * 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) * 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
AU2009302117B2 (en) 2008-10-08 2016-07-28 Cambridge Enterprise Limited Methods and compositions for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis
BRPI0921258A2 (pt) 2008-11-07 2018-10-23 4Sc Ag terapia combinatória compreendendo inibidor de dhodh e metotrexato para o tratamento de doença autoimune
MX2013013445A (es) 2011-05-16 2014-07-28 Genzyme Corp Induccion de tolerancia inmunologica utilizando metotrexato.

Also Published As

Publication number Publication date
EP2709627A1 (en) 2014-03-26
IL276879A (en) 2020-10-29
TN2013000472A1 (en) 2015-03-30
KR20190132551A (ko) 2019-11-27
PT2709627T (pt) 2020-12-24
DOP2013000268A (es) 2014-01-31
MY173304A (en) 2020-01-14
NZ716716A (en) 2018-06-29
RU2674036C2 (ru) 2018-12-04
CA2835819A1 (en) 2012-11-22
CL2013003298A1 (es) 2014-07-25
NI201300121A (es) 2014-02-28
KR20140040744A (ko) 2014-04-03
JP6174572B2 (ja) 2017-08-02
US20140135337A1 (en) 2014-05-15
EP3824890A1 (en) 2021-05-26
WO2012158362A1 (en) 2012-11-22
JP2018184466A (ja) 2018-11-22
KR102163285B1 (ko) 2020-10-08
CN109620830A (zh) 2019-04-16
MX2013013445A (es) 2014-07-28
RU2013155618A (ru) 2015-06-27
IL276879B (en) 2022-06-01
US20230372347A1 (en) 2023-11-23
ECSP13013081A (es) 2015-04-30
BR112013029501A2 (pt) 2017-01-24
JP6381707B2 (ja) 2018-08-29
AU2012256281B2 (en) 2017-06-15
MA35165B1 (fr) 2014-06-02
NZ742216A (en) 2018-10-26
SG194802A1 (en) 2013-12-30
CN103648501A (zh) 2014-03-19
KR20200116543A (ko) 2020-10-12
AU2012256281A1 (en) 2013-11-28
CN113209288A (zh) 2021-08-06
KR102316283B1 (ko) 2021-10-21
ZA201308315B (en) 2014-07-30
IL229245B (en) 2020-08-31
NZ617575A (en) 2016-10-28
PH12013502256A1 (en) 2022-04-08
US11672802B2 (en) 2023-06-13
JP2017141236A (ja) 2017-08-17
US20200360385A1 (en) 2020-11-19
GT201300278A (es) 2015-02-12
IL229245A0 (en) 2014-01-30
EP2709627A4 (en) 2014-11-12
ES2836823T3 (es) 2021-06-28
EP2709627B1 (en) 2020-09-23
UA117556C2 (uk) 2018-08-27
JP6694020B2 (ja) 2020-05-13
JP2014513722A (ja) 2014-06-05
CN110124039A (zh) 2019-08-16
CO6841993A2 (es) 2014-01-20

Similar Documents

Publication Publication Date Title
PE20140469A1 (es) Induccion de tolerancia inmunologica utilizando metotrexato
AR080218A1 (es) Productos de membranas corionicas inmunocompatibles
MX370404B (es) Uso de una terapia de combinación para inducir un injerto estable y a largo plazo.
MX2013013996A (es) Tratamiento contra el dolor utilizando celulas madre placentarias.
ECSP13013117A (es) Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina.
MX365007B (es) Uso de acido lipasa lisosomal para tratar la dificiencia de acido lipasa lisosomal en pacientes.
MX2016005574A (es) Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
NZ603482A (en) Bioactive renal cells
ES2721180T3 (es) Productos terapéuticos usando células adiposas y secreciones celulares
CL2012003401A1 (es) Compuestos derivados de carbamato de hexafluoroisopropilo, inhibidores de la enzima monoacil glicerol lipasa (mgl); proceso de preparacion; medicamento; compuestos intermediarios; composicion farmaceutica; y su uso para tratar o prevenir dolores agudos o cronicos, vertigos, dislipidemias y epilepsia, entre otras enfermedades.
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
TR201911076T4 (tr) Klorür içeriği azaltılmış fosfolipit içeren veya içermeyen hipotonik sulu bileşim.
WO2013126590A3 (en) Pharmaceutical composition comprising cd34+ cells
MX2016005824A (es) Metodo de cultivo celular.
BR112013006355A2 (pt) profármacos de éster de [3-(1-(1h-imidazol-4-il)etil-2-metilfenil] metanol para tratar doenças retinais
MX2022008475A (es) Composiciones y metodos para el tratamiento de esclerosis lateral amiotrofica (als) y otras enfermedades neurodegenerativas.
MX2014000567A (es) Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios.
CY1121973T1 (el) Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα
CR20110226A (es) Composición para tratar enfermedad
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
CO6670518A2 (es) Tratamiento de infecciones de clostridium difícile en pacientes bajo terapia con antibióticos
BR112015027569A2 (pt) compostos, composições, métodos e respectivos usos para tratar doenças por meio da inibição da atividade de tgf-ß
WO2014005153A3 (en) Methods for treating mds1-evi1 mediated cancer
CO2022011935A2 (es) Ésteres de ácido azelaico en el tratamiento o en la prevención de la dislipidemia y afecciones asociadas

Legal Events

Date Code Title Description
FC Refusal